Early Manifest Glaucoma Trial: design and baseline data.
about
Optic nerve head and fibre layer imaging for diagnosing glaucomaOptic nerve head and fibre layer imaging for diagnosing glaucomaLaser trabeculoplasty for open angle glaucomaMedical interventions for primary open angle glaucoma and ocular hypertensionQuality of Life in Glaucoma: A Review of the LiteratureDevelopment and validation of a computerized expert system for evaluation of automated visual fields from the Ischemic Optic Neuropathy Decompression Trial.Large-scale survey of unselected automated visual fields in a major reading center: patterns and data analysis.The Finnish evidence-based guideline for open-angle glaucoma.Dorzolamide and ocular blood flow in previously untreated glaucoma patients: a controlled double-masked study.Role of optic nerve imaging in glaucoma clinical practice and clinical trials.Performance of confocal scanning laser tomograph Topographic Change Analysis (TCA) for assessing glaucomatous progression.Diagnostic tools for glaucoma detection and management.Intraocular pressure reduction with a fixed treatment protocol in the Early Manifest Glaucoma Trial.Are you compliant with addressing glaucoma adherence?Detection of glaucoma progression by perimetry and optic disc photography at different stages of the disease: results from the Early Manifest Glaucoma Trial.New approach for the glaucoma detection with pupil perimetry.Comparing rates of retinal nerve fibre layer loss with GDxECC using different methods of visual-field progressionVisual function-specific perimetry to identify glaucomatous visual loss using three different definitions of visual field abnormalityOptic Disc Hemorrhage and Lamina Cribrosa Defects in Glaucoma Progression.Evaluation of a combined index of optic nerve structure and function for glaucoma diagnosis.Economic impact of primary open-angle glaucoma in Australia.Detection of progressive retinal nerve fiber layer thickness loss with optical coherence tomography using 4 criteria for functional progression.Effect of short-term oral valproic Acid on vision and visual field in retinitis pigmentosa.Glaucoma Progression Analysis software compared with expert consensus opinion in the detection of visual field progression in glaucoma.Effect of dorzolamide/timolol combination on the visual field in glaucoma.Subfoveal choroidal blood flow and central retinal function in early glaucoma.Optic nerve head morphology and visual field function in patients with AIDS and without infectious retinitis.Predicting glaucomatous progression in glaucoma suspect eyes using relevance vector machine classifiers for combined structural and functional measurementsProgression of visual field loss in untreated glaucoma patients and suspects in St Lucia, West Indies.Natural history of glaucoma.Detection of progression of glaucomatous visual field damage using the point-wise method with the binomial testNew insights into measurement variability in glaucomatous visual fields from computer modelling.Comprehensive Review of the Effects of Diabetes on Ocular Health.Compass: clinical evaluation of a new instrument for the diagnosis of glaucomaDeterminants of medication adherence to topical glaucoma therapy.Interobserver agreement on visual field progression in glaucoma: a comparison of methods.Incorporating life expectancy in glaucoma care.Glaucoma progression detection using nonlocal Markov random field prior.The Connective Tissue Components of Optic Nerve Head Cupping in Monkey Experimental Glaucoma Part 1: Global Change.The Role of the Immune System in Glaucoma: Bridging the Divide Between Immune Mechanisms in Experimental Glaucoma and the Human Disease.
P2860
Q24187597-2EC08F77-544E-43C9-BF01-DFE509F89E9AQ24236729-8FAD7A03-DDDC-41D6-8708-F3171400F4DFQ24242939-98F2A509-36BF-4F8C-B727-47C6977980F9Q24243220-002F8C87-7F10-4690-B9F0-5929581B0E94Q26747891-2F22C616-6E63-4250-8D30-72CD2A9179A2Q30445552-77FBABE0-BDBF-4AEA-A504-2650110BB49BQ30701842-63D17733-0F2A-4987-8E6C-121A02F8D817Q31134829-1B44EEC7-5F55-425C-A457-1F3FFE60B3CBQ32083506-A594C62B-BE2F-4201-B41C-98072617D8C0Q33320920-2B7B163F-82B5-4317-B998-B18FE71BAFBCQ33373974-92DA93E2-1440-4E2F-998F-A77997AA6EEAQ33387777-26E18B2D-8F0C-417B-B819-3D4BFD005639Q33541683-1237ED7A-B4C1-4DE6-B07D-7B5E89453F0EQ33617722-961DC216-E43F-4432-95B6-4F123EAB1CA4Q33626057-5B1872E2-6F29-4832-8E64-300C366E10E3Q33644601-B1A6202D-55DA-40ED-810A-FEDA4414695DQ33688852-178AE207-C88E-40E4-80D5-B1C696569C23Q33763998-B3DDE6A6-4EA3-4FA1-B435-975570048314Q33799235-ED47C9F0-EC11-4001-BD55-E7D46D5734E5Q33818741-F76F461C-33AA-44BA-8FC7-99169FAF405BQ33918990-BFC0D03F-962F-4E11-B9B3-87AE10EE95EBQ33926694-9E97F4FB-7AB9-49FC-8EB9-A21297956F52Q33939193-FCDC9CA5-464F-409D-86D5-D88518857CEFQ34089805-D98B0C01-4212-4496-ADAE-81EF9D3EE4C2Q34134877-82FED36E-8912-40F1-ADA1-9A9F1544D88BQ34135822-6B0FD12F-D8A4-4747-9A95-A9C96F92BE8EQ34181999-967E2672-D43D-4AF2-A98D-6706705057FCQ34199522-86E50F2B-16FD-4406-91C5-D4240AC5B502Q34330962-85CFD8FB-2A7D-4031-8CDE-DF9E42CBD6C4Q34571896-038F9B25-2959-4F51-83C7-DF4796B5F2EEQ35036603-559023CF-87B9-4E5E-AC06-D47575577722Q35080489-E9048E6B-6B41-4FE8-8DE0-F686A9F92271Q35099333-DACCB7DA-62A2-43C9-928F-3F51BEB380C6Q35217116-AD31C1C6-3A79-434A-AA47-0DBC13338F6FQ35243409-47C574C0-CFBE-48E9-9E0A-992A32DC0097Q35591121-F0ABA48E-87D5-410D-B17D-5DC7E596C70DQ35603517-5051E5A4-EC41-4E9E-8F18-D135F93544D5Q35774686-540BEE48-84D3-440A-9E8B-8F7E869CACAAQ35862272-982845CF-2802-451C-8C1D-A1F79DEE6882Q35950872-1B317D12-EBFE-4D74-B41C-BAE5CA30003C
P2860
Early Manifest Glaucoma Trial: design and baseline data.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Early Manifest Glaucoma Trial: design and baseline data.
@ast
Early Manifest Glaucoma Trial: design and baseline data.
@en
type
label
Early Manifest Glaucoma Trial: design and baseline data.
@ast
Early Manifest Glaucoma Trial: design and baseline data.
@en
prefLabel
Early Manifest Glaucoma Trial: design and baseline data.
@ast
Early Manifest Glaucoma Trial: design and baseline data.
@en
P2093
P1433
P1476
Early Manifest Glaucoma Trial: design and baseline data.
@en
P2093
P304
P356
10.1016/S0161-6420(99)90497-9
P577
1999-11-01T00:00:00Z